TD Asset Management Inc. cut its stake in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 21.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 67,844 shares of the biopharmaceutical company’s stock after selling 18,479 shares during the period. TD Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $27,275,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $207,000. A.R.T. Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $1,185,000. Squarepoint Ops LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $1,703,000. BlueMountain Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 92.5% in the first quarter. BlueMountain Capital Management LLC now owns 1,885 shares of the biopharmaceutical company’s stock valued at $679,000 after buying an additional 906 shares during the last quarter. Finally, New England Research & Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 17.4% in the second quarter. New England Research & Management Inc. now owns 1,145 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 170 shares during the last quarter. Institutional investors own 68.26% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 0.8222% during trading on Wednesday, reaching $384.0758. 122,690 shares of the company traded hands. The firm has a market capitalization of $40.26 billion, a price-to-earnings ratio of 56.0367 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a 12-month low of $325.35 and a 12-month high of $565.68. The firm’s 50 day moving average price is $381.53 and its 200 day moving average price is $389.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.73 by $0.40. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The business’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the company posted $3.47 EPS. Equities research analysts expect that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at http://www.dailypolitical.com/2016/11/30/td-asset-management-inc-has-27275000-stake-in-regeneron-pharmaceuticals-inc-regn.html.

REGN has been the subject of several recent analyst reports. Vetr upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 target price for the company in a research note on Tuesday, August 2nd. Cowen and Company reiterated a “hold” rating and issued a $430.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Robert W. Baird downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and cut their target price for the company from $505.00 to $448.00 in a research note on Friday, August 5th. Canaccord Genuity reiterated a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Brean Capital reiterated a “buy” rating and issued a $489.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $468.87.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the transaction, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,806,250. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the transaction, the director now directly owns 36,500 shares in the company, valued at approximately $15,670,910. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.